Literature DB >> 15577829

Loss of syk kinase during IgE-mediated stimulation of human basophils.

Donald Macglashan1, Katsushi Miura.   

Abstract

BACKGROUND: Ongoing secretion from human basophils is a balance of activation and deactivation events. Recent studies have focused on downregulatory steps that appear to modify the presence of the activated state of various signaling molecules. We now examine downregulation regulated by mechanisms related to proteasome processing.
OBJECTIVE: To determine the long-term effects of FcepsilonRI aggregation on expression of syk kinase.
METHODS: Peripheral blood basophils were examined for changes in the expression of syk kinase after stimulation with optimal and suboptimal stimulation.
RESULTS: Stimulation results in a 20% loss of syk in 1 hour and an 80% loss of syk in longer incubations (>18 hours). Loss of syk in this time frame can occur at levels of stimulation that do not result in observable mediator release. Loss of syk occurs after stimulation with either anti-IgE antibody or antigen. Activation is shown to result in c-Cbl phosphorylation, and its association with syk and immunoblotting reveals the appearance of a ladder of syk species with molecular weights that are consistent with ubiquitylation of syk. Stimulation in the presence of a proteasome inhibitor such as lactacystin A results in the sustained presence of very high-molecular-weight ubiquitylated species, although it does not alter the presence of the syk ladder.
CONCLUSIONS: Although the loss of syk is probably too slow to account for downregulation of ongoing secretion of histamine or leukotriene C4 release, it may lead to longer-term alterations in basophil function that explain characteristics of clinical procedures like rapid drug desensitization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15577829     DOI: 10.1016/j.jaci.2004.08.037

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  29 in total

1.  In vitro desensitization of human skin mast cells.

Authors:  Wei Zhao; Gregorio Gomez; Matthew Macey; Christopher L Kepley; Lawrence B Schwartz
Journal:  J Clin Immunol       Date:  2011-10-19       Impact factor: 8.317

Review 2.  Degradation of activated protein kinases by ubiquitination.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

3.  Polymerization of actin does not regulate desensitization in human basophils.

Authors:  Donald MacGlashan; Natalia Vilariño
Journal:  J Leukoc Biol       Date:  2009-01-15       Impact factor: 4.962

4.  Autoantibodies to IgE and FcεRI and the natural variability of spleen tyrosine kinase expression in basophils.

Authors:  Donald MacGlashan
Journal:  J Allergy Clin Immunol       Date:  2018-06-01       Impact factor: 10.793

Review 5.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

6.  Stability of Syk protein and mRNA in human peripheral blood basophils.

Authors:  Donald MacGlashan
Journal:  J Leukoc Biol       Date:  2016-03-15       Impact factor: 4.962

7.  Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.

Authors:  Donald MacGlashan; Lee A Honigberg; Ashley Smith; Joseph Buggy; John T Schroeder
Journal:  Int Immunopharmacol       Date:  2011-01-14       Impact factor: 4.932

8.  CD33 recruitment inhibits IgE-mediated anaphylaxis and desensitizes mast cells to allergen.

Authors:  Shiteng Duan; Cynthia J Koziol-White; William F Jester; Scott A Smith; Corwin M Nycholat; Matthew S Macauley; Reynold A Panettieri; James C Paulson
Journal:  J Clin Invest       Date:  2019-02-18       Impact factor: 14.808

9.  Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils.

Authors:  Susan S Ishmael; Donald W MacGlashan
Journal:  J Leukoc Biol       Date:  2009-11-04       Impact factor: 4.962

10.  Clinical efficacy and immune regulation with peanut oral immunotherapy.

Authors:  Stacie M Jones; Laurent Pons; Joseph L Roberts; Amy M Scurlock; Tamara T Perry; Mike Kulis; Wayne G Shreffler; Pamela Steele; Karen A Henry; Margaret Adair; James M Francis; Stephen Durham; Brian P Vickery; Xiaoping Zhong; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2009-07-03       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.